Amicus Therapeutics, Inc.
FOLD
$9.92
$0.141.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.29% | 23.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.29% | 23.50% | |||
| Cost of Revenue | 27.93% | 30.08% | |||
| Gross Profit | 7.26% | 22.83% | |||
| SG&A Expenses | 6.50% | -7.93% | |||
| Depreciation & Amortization | 1.19% | 0.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.03% | 21.97% | |||
| Operating Income | 540.93% | 2.26% | |||
| Income Before Tax | 278.69% | -6.30% | |||
| Income Tax Expenses | 223.88% | 43.89% | |||
| Earnings from Continuing Operations | 170.87% | -12.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 170.87% | -12.61% | |||
| EBIT | 540.93% | 2.26% | |||
| EBITDA | 710.52% | 3.19% | |||
| EPS Basic | 170.83% | -12.34% | |||
| Normalized Basic EPS | 296.05% | 3.54% | |||
| EPS Diluted | 170.83% | -12.34% | |||
| Normalized Diluted EPS | 294.92% | 3.54% | |||
| Average Basic Shares Outstanding | 0.07% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.71% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||